Substrate reduction therapy in the infantile form of Tay-Sachs disease.

Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two...

詳細記述

書誌詳細
主要な著者: Bembi, B, Marchetti, F, Guerci, V, Ciana, G, Addobbati, R, Grasso, D, Barone, R, Cariati, R, Fernandez-Guillen, L, Butters, T, Pittis, MG
フォーマット: Journal article
言語:English
出版事項: 2006
その他の書誌記述
要約:Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.